Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19

For those who want to continue doing things the stupid way, the way Big Pharma brainwashes society to do things, here's the latest on Guangdong Zhongsheng Raynovent Biotech's narrow-spectrum, 3CLpro inhibitor, RAY1216 (leritrelvir), which prefers ritonavir